Differentiation and activation antigens on blood mononuclear cells in lymphocytic leukemia before and during IFN-Alpha 2B therapy

J. Demeter, K. Pálóczi, Gyorgy Bibok, Dezso Lehoczky

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Expression of differentiation and activation antigens on peripheral blood mononuclear cells of four chronic lymphocytic leukaemia (CLL) patients was studied before and during interferon-alpha2b therapy. Patients had clinical stage B(II) disease, a lymphocyte count of over 60 G/l and a lymphocyte doubling time shorter than 12 months. One of the patients unresponsive to previous chemotherapy experienced a substantial decrease of the lymphocyte count during interferon-alpha2b (IFN-alpha2b) therapy, with a nadir at one fifth of the initial value while on this therapy. The lymphocyte count decreased slightly in a further patient, while it increased in two patients. Treatment with IFN-alpha2b left the phenotype of CLL lymphocytes essentially unchanged. The elevated serum β-2 microglobulin values increased further during treatment with the exception of the CLL patient responsive to IFN-alpha2b therapy. The clinical stage of the disease did not change in any of the patients when evaluated according to the criteria of the International Workshop on CLL. Further studies are necessary to determine which of the CLL patients benefit from therapy with interferon-alpha2b.

Original languageEnglish
JournalLeukemia
Volume6
Issue numberSUPPL. 3
Publication statusPublished - 1992

Fingerprint

Lymphoid Leukemia
Differentiation Antigens
Blood Cells
B-Cell Chronic Lymphocytic Leukemia
Interferons
Lymphocyte Count
Therapeutics
Lymphocytes
Phenotype
Education
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Differentiation and activation antigens on blood mononuclear cells in lymphocytic leukemia before and during IFN-Alpha 2B therapy. / Demeter, J.; Pálóczi, K.; Bibok, Gyorgy; Lehoczky, Dezso.

In: Leukemia, Vol. 6, No. SUPPL. 3, 1992.

Research output: Contribution to journalArticle

@article{15709be1978048d7a1967cb26ab5a390,
title = "Differentiation and activation antigens on blood mononuclear cells in lymphocytic leukemia before and during IFN-Alpha 2B therapy",
abstract = "Expression of differentiation and activation antigens on peripheral blood mononuclear cells of four chronic lymphocytic leukaemia (CLL) patients was studied before and during interferon-alpha2b therapy. Patients had clinical stage B(II) disease, a lymphocyte count of over 60 G/l and a lymphocyte doubling time shorter than 12 months. One of the patients unresponsive to previous chemotherapy experienced a substantial decrease of the lymphocyte count during interferon-alpha2b (IFN-alpha2b) therapy, with a nadir at one fifth of the initial value while on this therapy. The lymphocyte count decreased slightly in a further patient, while it increased in two patients. Treatment with IFN-alpha2b left the phenotype of CLL lymphocytes essentially unchanged. The elevated serum β-2 microglobulin values increased further during treatment with the exception of the CLL patient responsive to IFN-alpha2b therapy. The clinical stage of the disease did not change in any of the patients when evaluated according to the criteria of the International Workshop on CLL. Further studies are necessary to determine which of the CLL patients benefit from therapy with interferon-alpha2b.",
author = "J. Demeter and K. P{\'a}l{\'o}czi and Gyorgy Bibok and Dezso Lehoczky",
year = "1992",
language = "English",
volume = "6",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Differentiation and activation antigens on blood mononuclear cells in lymphocytic leukemia before and during IFN-Alpha 2B therapy

AU - Demeter, J.

AU - Pálóczi, K.

AU - Bibok, Gyorgy

AU - Lehoczky, Dezso

PY - 1992

Y1 - 1992

N2 - Expression of differentiation and activation antigens on peripheral blood mononuclear cells of four chronic lymphocytic leukaemia (CLL) patients was studied before and during interferon-alpha2b therapy. Patients had clinical stage B(II) disease, a lymphocyte count of over 60 G/l and a lymphocyte doubling time shorter than 12 months. One of the patients unresponsive to previous chemotherapy experienced a substantial decrease of the lymphocyte count during interferon-alpha2b (IFN-alpha2b) therapy, with a nadir at one fifth of the initial value while on this therapy. The lymphocyte count decreased slightly in a further patient, while it increased in two patients. Treatment with IFN-alpha2b left the phenotype of CLL lymphocytes essentially unchanged. The elevated serum β-2 microglobulin values increased further during treatment with the exception of the CLL patient responsive to IFN-alpha2b therapy. The clinical stage of the disease did not change in any of the patients when evaluated according to the criteria of the International Workshop on CLL. Further studies are necessary to determine which of the CLL patients benefit from therapy with interferon-alpha2b.

AB - Expression of differentiation and activation antigens on peripheral blood mononuclear cells of four chronic lymphocytic leukaemia (CLL) patients was studied before and during interferon-alpha2b therapy. Patients had clinical stage B(II) disease, a lymphocyte count of over 60 G/l and a lymphocyte doubling time shorter than 12 months. One of the patients unresponsive to previous chemotherapy experienced a substantial decrease of the lymphocyte count during interferon-alpha2b (IFN-alpha2b) therapy, with a nadir at one fifth of the initial value while on this therapy. The lymphocyte count decreased slightly in a further patient, while it increased in two patients. Treatment with IFN-alpha2b left the phenotype of CLL lymphocytes essentially unchanged. The elevated serum β-2 microglobulin values increased further during treatment with the exception of the CLL patient responsive to IFN-alpha2b therapy. The clinical stage of the disease did not change in any of the patients when evaluated according to the criteria of the International Workshop on CLL. Further studies are necessary to determine which of the CLL patients benefit from therapy with interferon-alpha2b.

UR - http://www.scopus.com/inward/record.url?scp=0026736037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026736037&partnerID=8YFLogxK

M3 - Article

VL - 6

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - SUPPL. 3

ER -